These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22353500)

  • 1. Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab.
    Melichar B; Králíčková P; Hyšpler R; Kalábová H; Cerman J; Holečková P; Studentová H; Malířová E
    Hepatogastroenterology; 2012; 59(114):366-71. PubMed ID: 22353500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
    Fakih MG; Wilding G; Lombardo J
    Clin Colorectal Cancer; 2006 Jul; 6(2):152-6. PubMed ID: 16945172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab therapy and symptomatic hypomagnesemia.
    Schrag D; Chung KY; Flombaum C; Saltz L
    J Natl Cancer Inst; 2005 Aug; 97(16):1221-4. PubMed ID: 16106027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
    Stintzing S; Fischhaber D; Mook C; Modest DP; Giessen C; Schulz C; Haas M; Boeck S; Michl M; Stemmler J; Laubender RP; Heinemann V
    Anticancer Drugs; 2013 Oct; 24(9):969-74. PubMed ID: 23863616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
    Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
    Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
    Tejpar S; Piessevaux H; Claes K; Piront P; Hoenderop JG; Verslype C; Van Cutsem E
    Lancet Oncol; 2007 May; 8(5):387-94. PubMed ID: 17466895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab for the treatment of colorectal cancer.
    Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
    N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
    Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
    N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
    Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
    Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
    George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
    J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin.
    Kono T; Satomi M; Asama T; Ebisawa Y; Chisato N; Suno M; Karasaki H; Furukawa H; Matsubara K
    J Gastrointest Oncol; 2010 Dec; 1(2):97-101. PubMed ID: 22811813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
    Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
    Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
    Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab-induced cutaneous toxicity.
    Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.
    Cao Y; Liao C; Tan A; Liu L; Gao F
    Chemotherapy; 2010; 56(6):459-65. PubMed ID: 21088398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.